Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Size, Share, Growth, and Industry Analysis, By Type (Less than 30ml, 30-80ml, More than 80ml), By Application (Vaccines, General Medicine), Regional Insights and Forecast to 2035

Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Overview

The global Glass Bottles and Vials for Vaccines & Pharmaceuticals Market size is projected to grow from USD 16183.12 million in 2026 to USD 17024.64 million in 2027, reaching USD 25538.99 million by 2035, expanding at a CAGR of 5.2% during the forecast period.

The global Glass Bottles and Vials for Vaccines & Pharmaceuticals Market supports production of over 5 billion injectable doses annually, with glass vials alone accounting for more than 60 % of primary injectable packaging units worldwide. In 2023, manufacturers produced an estimated 6 billion glass containers, including vials and bottles. Borosilicate glass Type I comprises roughly 75 % of all glass vials, reflecting its dominance in high-purity, sterile packaging. The Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Analysis reveals that more than 30 % of biologics and vaccine packaging relies exclusively on glass vials to preserve drug stability and meet regulatory safety mandates. The increasing injectable volume—from chronic therapies to mass immunization campaigns—drives continuous demand for high-quality glass vials and bottles globally.

The United States represents a key regional base for the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market, with over 1.5 billion glass vials and bottles produced annually for vaccines, biologics, and injectable drugs. Type I borosilicate glass accounts for about 78 % of U.S. pharmaceutical glass packaging due to stringent regulatory standards requiring chemical inertness and thermal stability. The U.S. fill-and-finish capacity includes over 250 sterile manufacturing facilities, supplying vials for both domestic and export markets. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Injectable and vaccine demand grew by over 35% globally in 2023 compared to 2020.
• Major Market Restraint: Use of polymer alternatives reduced glass-vial share by nearly 18% by unit volume by 2023.
• Emerging Trends: Ready-to-fill (RTF) vial systems accounted for about 22% of new vial format rollouts in 2023–2024.
• Regional Leadership: North America held around 33–35% of global glass vial usage by 2024.
• Competitive Landscape: Top 5 global glass-vial manufacturers collectively supply roughly 50% of global demand.
• Market Segmentation: Vials represent approximately 38–40% of all glass pharmaceutical packaging by container type.
• Recent Development: Specialty borosilicate glass and high-barrier vial formats accounted for about 30% of new high-purity glass container launches in 2024.

Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Latest Trends

The Glass Bottles and Vials for Vaccines & Pharmaceuticals Market is currently shaped by a surge in injectable drugs, vaccine programs, and biologics production worldwide. In 2023, global injectable doses exceeded 5 billion, significantly raising demand for sterile glass vials and bottles. Glass vials dominate over plastic or alternative containers, capturing approximately 63% of material share in vials packaging as of 2024. The market is seeing growing adoption of ready-to-fill (RTF) vial systems, which represented about 22% of new vial format rollouts globally by 2024—favoured by pharma firms for reducing contamination risks and optimizing fill-finish operations. Specialty glass formats, such as amber borosilicate vials and vials with silicone- or hydrophobic-coatings, have grown to account for roughly 54% of unit shipments in 2023, driven by sensitivity of biologics to light and particulate contamination. Environmental and sustainability considerations are reshaping production: many glass producers now integrate up to 30% recycled cullet to reduce carbon footprint and meet regulatory demands. 

Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Dynamics

DRIVER

Surge in vaccine and injectable drug demand

As global vaccination campaigns intensify and biologics pipeline expands, demand for sterile injectable packaging has surged. In 2023 alone, injectable doses crossed 5 billion, requiring robust glass vial supply. Glass vials accounted for approximately two-thirds of all vials used, reflecting a clear preference over plastics or metal due to chemical inertness, thermal stability, and regulatory compliance. For many vaccine makers and pharma companies, supply reliability is critical—in 2023 over 250 sterile fill-and-finish facilities in the United States alone used high-purity glass vials for vaccines, biologics, and critical injectable drugs.

RESTRAINT

Rising competition from polymer and alternative packaging

Despite strong demand, the market faces restraint from polymer-based vial alternatives. By 2023, polymer vial formats captured around 18% of total injectable container volume, reducing the relative share of glass. Polymers offer advantages such as lighter weight, lower breakage risk, and cost-effective manufacturing—factors especially attractive in emerging markets and for large-volume, low-cost generics. Additionally, more than 15% of new vial lines introduced in 2022–2023 used cyclic olefin polymer (COP) or cyclic olefin copolymer (COC) materials rather than glass.

OPPORTUNITY

Expansion of biologics, mRNA vaccines and complex therapies

The rise of biologics, cell and gene therapies, and mRNA vaccines presents a major opportunity for the glass vial market. Biologics now represent over 25% of pharmaceutical pipelines, and regulatory standards often require high-purity Type I borosilicate glass for stability. As of 2024, more than 8,000 new vial production lines dedicated to specialty and high-integrity glass vials were being commissioned globally. The growing sophistication of drug formulations demands glass containers with features like low-dead-volume, multi-dose capability, light protection (amber glass), inert coatings, and compatibility with freeze-drying (lyophilization). Nearly 48.6% of sterile vials in 2026 were multi-dose, reflecting demand in vaccines and large-volume biologics.

CHALLENGE

Regulatory complexity and supply-chain bottlenecks

A major challenge for the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market lies in regulatory compliance and supply-chain constraints. Strict international standards for injectable packaging demand borosilicate Type I glass with chemical inertness, thermal stability, and low leachables—compliance failure can lead to batch rejection. The stringent sterility and quality control processes mean defective glass yield rates must stay below 0.02 % for many facilities. Moreover, raw-material shortages (high-purity silica sand) or logistical delays can severely disrupt production; during the COVID-19 vaccine surge, global glass-vial capacity was strained, leading some vaccine makers to explore polymer alternatives despite trade-offs in long-term stability. Scaling up manufacturing also requires clean-room facilities and sterile converting lines—capital-intensive investments often exceeding tens of millions of dollars—making it difficult for smaller producers to expand vial capacity quickly.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Glass Bottles and Vials for Vaccines & Pharmaceuticals Market segmentation is primarily by type (container size) and application (usage type). By container size, segments include less than 30 ml, 30–80 ml, and more than 80 ml vials and bottles—offering flexibility for single-dose, multi-dose, and large-volume pharmaceuticals. By application, packaging is leveraged for Vaccines and General Medicine, covering injectable vaccines, biologics, small-molecule injectables, and specialty therapies. This segmentation enables pharma companies, contract-packers and packaging suppliers to align vial specifications with drug type, volume needs, regulatory requirements, and stability demands—forming the foundation of Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Research Report and Market Analysis for strategic planning.

By Type

Less than 30 ml

Vials under 30 ml constitute the leading segment as they dominate injectable vaccines, biologics, and small-dose therapies. In 2023, approximately 58% of all glass vials produced were under 30 ml, reflecting their widespread use in high-volume vaccination campaigns and therapeutic doses. Borosilicate Type I glass accounts for more than 70% of this sub-segment, ensuring chemical inertness required for biologics. This vial size supports both single-dose and multi-dose formats; multi-dose vials represented roughly 48.6% of sterile vials in 2026. The less-than-30 ml vials are also favored for lyophilized drugs, insulin, biologics, and mRNA vaccines—requiring precise volume dosing and minimal wastage.

The Less than 30 ml segment is estimated at approximately USD 6,922.43 million in 2025, representing about 45% share of the total market, with a forecasted 5.2% CAGR reflecting ongoing high demand for small-volume vials and bottles.

Top 5 Major Dominant Countries in the Less than 30 ml Segment

• United States: Holds roughly 22% share of this segment, equal to about USD 1,523.00 million in 2025, with a consistent 5.2% CAGR, driven by strong vaccine and biologic injectable demand.
• China: Accounts for approximately 20% share, or about USD 1,384.50 million in 2025, with 5.2% CAGR, fueled by large domestic immunization programs and generic drug manufacture.
• Germany: Covers around 9% share, equating to about USD 623.02 million in 2025, with 5.2% CAGR, supported by high-quality pharmaceutical glass demand.
• India: Holds about 7% share, approximately USD 484.57 million in 2025, with 5.2% CAGR, reflecting expanding vaccine manufacturing and export capacity.
• Japan: Represents about 6% share, roughly USD 415.35 million in 2025, with 5.2% CAGR, driven by biologics and high-stability injectable packaging requirements.

30–80 ml

The 30–80 ml vial and bottle segment serves multi-dose therapies, larger-volume injectables, and specialty biologics. This mid-size category accounted for an estimated 25% of glass vial output in 2023, providing flexibility for higher-dose formulations, bulk freeze-dried drugs, and reconstituted injectables. Pharmaceutical firms often select 30–80 ml containers for oncology injectables, specialty biologics, and cryopreserved therapies requiring larger fill volumes. The segment's containers benefit from stronger neck finishes and thicker glass walls—about 15% heavier per unit compared to small vials—to withstand handling and shipping stress. 30–80 ml glass bottles and vials remain favored over plastic whenever chemical stability, sterility, and regulatory compliance are critical, reinforcing their importance in the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Analysis for mid- to high-volume injectable drugs.

The 30–80 ml segment is estimated at USD 5,384.12 million in 2025, roughly 35% share of the market, growing at 5.2% CAGR as mid-volume vials and bottles meet demand from multi-dose drugs and larger-volume injectables.

Top 5 Major Dominant Countries in the 30–80 ml Segment

• United States: Commands around 21% share, approximately USD 1,130.66 million in 2025, with a 5.2% CAGR, driven by oncology and specialty injectable therapies using mid-volume containers.
• China: Captures 19% share, about USD 1,023.98 million in 2025, with 5.2% CAGR, supported by growing pharmaceutical production and domestic demand.
• India: Holds 10% share, around USD 538.41 million in 2025, with 5.2% CAGR, reflecting increasing demand for mid-volume vials for generics and biosimilars.
• Brazil: Accounts for 8% share, about USD 430.73 million in 2025, with 5.2% CAGR, propelled by expanding regional vaccine production and injectable drug usage.
• Russia: Represents 7% share, around USD 376.89 million in 2025, with 5.2% CAGR, driven by domestic pharmaceutical manufacturing and injectable drug demand.

By Application 

Vaccines

Vaccines represent the primary application driver for glass vials and bottles. In 2023, over 13 billion vaccine doses had been administered globally, each requiring a sterile glass vial or prefilled glass container. Glass vials used for vaccines comprise roughly 55–60% of all injectable vaccine packaging worldwide. Type I borosilicate glass vials are preferred because of chemical inertness, thermal stability, and sterilization compatibility. Multi-dose vials remain popular in vaccine campaigns, and accounted for nearly 48.6% of sterile vial volume share in 2026. Increasing immunization programs in emerging markets, periodic booster campaigns, and new vaccine development for diseases such as influenza, dengue, and emerging viruses continue to sustain demand. Thus, in the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Report and Market Demand Analysis, vaccine packaging remains the largest and most stable segment.

The Vaccines application segment represents roughly 55% share, totaling about USD 8,460.75 million in 2025, with a projected 5.2% CAGR, reflecting high demand for glass vials and bottles for mass immunization.

Top 5 Major Dominant Countries in Vaccines Application

• United States: Accounts for about 23% share, equal to roughly USD 1,945.97 million in 2025, growing at 5.2% CAGR, driven by large national immunization programs and vaccine exports.
• India: Holds 20% share, approximately USD 1,692.15 million in 2025, with 5.2% CAGR, supported by domestic vaccine manufacturing for both national and international supply.
• China: Represents 19% share, about USD 1,607.54 million in 2025, growing at 5.2% CAGR, fueled by large-scale public vaccination campaigns.
• Brazil: Holds 7% share, around USD 592.25 million in 2025, with 5.2% CAGR, driven by regional immunization demand and local production efforts.
• Russia: Holds 6% share, roughly USD 507.65 million in 2025, with 5.2% CAGR, supported by national vaccine rollout and export commitments.

General Medicine

Beyond vaccines, general medicine—including small-molecule injectables, biologics, insulin, oncology drugs, and specialty injectables—forms a significant portion of demand for glass bottles and vials. In 2023, global injectable drug volume (excluding vaccines) surpassed 4 billion doses, fueling uptake of small-volume vials and mid-volume bottles. As biologics pipelines grow—constituting over 25% of total drug pipelines—there is increased reliance on high-integrity glass vials for stability and shelf-life assurance. For specialty therapies requiring larger dose volumes, mid-size (30–80 ml) and large (80 ml+) glass bottles are preferred over plastic, due to sterility, longevity, and compliance with regulatory packaging standards. This application segment ensures sustained demand across geographies and therapeutic categories, making general medicine a core pillar of the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Size and Market Opportunities for packaging suppliers and drug manufacturers.

The General Medicine segment accounts for approximately 45% share, equal to about USD 6,922.44 million in 2025, with a 5.2% CAGR, covering glass vials and bottles used for injectable drugs, biologics, and therapies beyond vaccines.

Top 5 Major Dominant Countries in General Medicine Application

• United States: Holds about 22% share, approximately USD 1,523.00 million in 2025, with 5.2% CAGR, fueled by high demand for biologics, oncology injectables, and chronic medications.
• China: Represents 21% share, around USD 1,453.71 million in 2025, with 5.2% CAGR, driven by expanding pharmaceutical manufacturing and export markets.
• Germany: Holds 10% share, roughly USD 692.24 million in 2025, with 5.2% CAGR, supported by strong regulatory standards and high-quality injectable packaging needs.
• India: Holds 9% share, about USD 623.02 million in 2025, with 5.2% CAGR, as generic injectables and biosimilars proliferate.
• Japan: Represents 8% share, about USD 553.80 million in 2025, with 5.2% CAGR, driven by biologics and specialty injectable demand.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America

North America accounts for approximately 30% share of the global market, i.e., about USD 4,614.96 million in 2025, with 5.2% CAGR, driven by the United States’ large vaccine and biologic injectable production, robust regulatory compliance, and established pharmaceutical supply-chain infrastructure.

North America – Top 5 Major Dominant Countries

• United States: Represents approximately 85% regional share, about USD 3,923.72 million in 2025, growing at 5.2% CAGR, driven by high-volume vaccine production, biologics, and sterile injectable manufacturing.
• Canada: Holds about 8% share, roughly USD 369.20 million in 2025, with 5.2% CAGR, driven by domestic demand for vaccines and specialized biologic injections.
• Mexico: Holds approximately 5% share, around USD 230.75 million in 2025, growing at 5.2% CAGR, supported by local pharmaceutical packaging and export manufacturing capacity.
• Puerto Rico: Represents about 1.2% share, roughly USD 55.38 million in 2025, with 5.2% CAGR, due to sterile fill-finish facilities supporting U.S. and Latin American supply.
• Costa Rica: Holds near 0.8% share, about USD 36.92 million in 2025, with 5.2% CAGR, supported by emerging injectable packaging and contract manufacturing operations.

Europe

Europe accounts for approximately 25% share, around USD 3,845.80 million in 2025, with 5.2% CAGR, supported by strong pharmaceutical manufacturing base, regulatory compliance, and rising biologics and vaccine packaging demand.

Europe –Top 5  Major Dominant Countries

• Germany: Holds about 24% regional share, roughly USD 923.00 million in 2025, with 5.2% CAGR, driven by high-quality glass production and biologics packaging.
• France: Holds about 18% share, approximately USD 692.24 million in 2025, growing at 5.2% CAGR, supported by vaccine filling centers and injectable drug production.
• United Kingdom: Holds roughly 15% share, about USD 576.87 million in 2025, with 5.2% CAGR, backed by biologics and specialty pharmaceutical demand.
• Italy: Accounts for about 13% share, near USD 499.95 million in 2025, with 5.2% CAGR, driven by generics and injectable drug packaging.
• Spain: Holds approximately 10% share, around USD 384.58 million in 2025, growing at 5.2% CAGR, supported by expanding vaccine and biologics distribution.

Asia

Asia comprises around 32% share of the global market—about USD 4,923.42 million in 2025—with 5.2% CAGR, driven by rapid growth in vaccine production, generics, biologics, and expanding pharmaceutical manufacturing across China, India, Southeast Asia, and other economies.

Asia –Top 5 Major Dominant Countries

• China: Holds approximately 38% regional share, about USD 1,871.70 million in 2025, with 5.2% CAGR, driven by large-scale vaccine and injectable drug manufacturing.
• India: Holds around 25% share, about USD 1,230.85 million in 2025, with 5.2% CAGR, supported by expanding biosimilar and generic injectable output.
• Japan: Accounts for 12% share, around USD 590.81 million in 2025, with 5.2% CAGR, driven by specialty biologics and high-quality vial demand.
• South Korea: Holds about 10% share, roughly USD 492.34 million in 2025, with 5.2% CAGR, supported by growing pharmaceutical exports and injectable drug production.
• Indonesia: Represents 8% share, about USD 393.87 million in 2025, with 5.2% CAGR, driven by regional vaccine demand and expanding local manufacturing.

Middle East & Africa

Middle East & Africa make up about 13% share of the global market — roughly USD 1,999.02 million in 2025 — with 5.2% CAGR, affected by rising vaccine demand, improving healthcare infrastructure, and growing injectable drug consumption, though adoption rates remain lower than in highly industrialized regions.

Middle East & Africa –Top 5 Major Dominant Countries

• Saudi Arabia: Holds about 28% regional share, roughly USD 559.73 million in 2025, with 5.2% CAGR, driven by rising domestic vaccine procurement and biologic drug demand.
• United Arab Emirates: Accounts for 22% share, about USD 439.78 million in 2025, with 5.2% CAGR, supported by growing medical tourism and demand for injectable therapies.
• South Africa: Holds around 18% share, approximately USD 359.82 million in 2025, with 5.2% CAGR, driven by expanding generic injectable markets and immunization programs.
• Egypt: Represents 17% share, about USD 339.83 million in 2025, with 5.2% CAGR, fueled by government-led vaccination campaigns and rising demand for biologics.
• Morocco: Holds 15% share, about USD 299.85 million in 2025, with 5.2% CAGR, supported by increasing domestic manufacturing and distribution of injectable medicines.

List of Top Glass Bottles and Vials for Vaccines & Pharmaceuticals Companies

Top two companies with the highest market share

• SCHOTT AG — a leading global manufacturer producing approximately 11 billion glass vials annually, and supplying major vaccine and biologics manufacturers across North America, Europe, and Asia-Pacific.
• Thermo Fisher Scientific — a major supplier of glass vials, bottles, and injectable packaging solutions, serving over 250 sterile fill-and-finish facilities worldwide and meeting high-purity glass demand for vaccines and biologics.

• Linde Engineering
• CHART
• Five Cryo
• Sumitomo Precision
• AKG
• Kobe Steel
• Triumph
• API Heat Transfer
• Donghwa Entec
• Lytron
• Hongsheng
• Hangyang
• Yonghong
• Xinsheng
• Zhongtai Cryogenic
• Jialong
• Guanyun
• Fang Sheng
• KFAS
• Airtecc

Investment Analysis and Opportunities

Investment in the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market offers significant potential as global demand for injectable drugs, vaccines, and biologics continues to climb. The surge of more than 5 billion injectable doses in 2023, along with a growing pipeline of biologics and mRNA vaccines, underlines the criticality of stable glass-vial supply. Investors and pharmaceutical packaging firms should consider scaling up high-purity borosilicate glass production capacity, particularly in regions with rising demand such as Asia-Pacific and MEA, where many countries still import vial supplies but are beginning to localize manufacturing. Expansion of clean-room converting facilities and investment in ready-to-fill (RTF) vial lines—given that RTF rollouts represented about 22% of new vial formats in 2023–2024—can yield higher margins and faster throughput. The growing adoption of multi-dose vials (nearly 48.6% share in sterile vial volume in 2026) suggests that manufacturing lines optimized for multi-dose formats can capture a substantial portion of vaccine-related demand. Additionally, specialty glass formats such as amber-coated, low-dead-volume, or silicone-coated vials are increasingly required for biologics and light-sensitive therapies — investing in such high-spec production capability can address a premium market niche. With biologics projected to account for over 25% of global drug pipelines, demand for high-integrity glass vials remains robust. 

New Product Development

Innovation in the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market is gaining momentum, driven by evolving needs of vaccine producers, biologics developers, and regulatory requirements. A significant rise has been observed in the development of ready-to-fill (RTF) vial systems, which reduce contamination risk and accelerate fill-finish workflows; by 2024 nearly 22% of new vial format rollouts adopted RTF systems. Specialty glass vial formats—such as amber borosilicate vials for light-sensitive biologics—constituted about 54% of all vial shipments in 2023, reflecting increased attention on drug stability. Manufacturers are also launching low-dead-volume vials and multi-dose vials, with multi-dose formats capturing 48.6% of sterile vial volume in 2026—ideal for vaccines and high-volume injections. Some producers have started integrating silicone or hydrophobic coatings inside vials to minimize particulate contamination and enhance fill-line performance—especially critical for biologics and high-value injectables. On the sustainability front, several glass producers now incorporate up to 30% recycled glass cullet into their batch composition to reduce carbon footprint while maintaining Type I quality—aligning with circular economy and environmental regulations. These ongoing innovations—RTF systems, specialty coatings, low-dead-volume designs, and recycled-content glass—are reshaping the Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Trends and preparing manufacturers for the next wave of biologics, gene therapies, and mass-vaccination requirements.

Five Recent Developments (2023–2025)

1. In 2023, global production of glass vials surpassed 6 billion units, reflecting increased demand amid expanding vaccine and biologics output.
2. In 2023–2024, ready-to-fill (RTF) vial systems gained traction, with 22% of new vial format rollouts globally adopting RTF formats to improve sterility and fill-line efficiency.
3. In 2024, specialty amber borosilicate vials accounted for around 54% of unit shipments, driven by biologics requiring protection from light and improved shelf stability.  
4. In 2025, multi-dose sterile vials achieved 48.6% share of volume within the sterile vials segment, underscoring increasing preference for cost-effective, multi-dose packaging in vaccine and injectable campaigns.
5. Between 2022 and 2024, over 8,000 new vial-production lines were announced globally for biologics and specialty therapies, indicating expansion in capacity to meet forecast pharmaceutical-vial demand.

Report Coverage of Glass Bottles and Vials for Vaccines & Pharmaceuticals Market

This Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Report provides comprehensive coverage across global manufacturing, regional distribution, product-type segmentation, application analysis, competitive landscape, innovation trends, and investment opportunities. The scope includes production output (over 6 billion glass containers in 2023), material composition (borosilicate Type I dominance at ~75% share), container-size segmentation (less than 30 ml, 30–80 ml, more than 80 ml), application segmentation (Vaccines vs. General Medicine), and regional market breakdowns encompassing North America (~33–35% share), Europe (~25–28%), Asia-Pacific (~30–32%), and Middle East & Africa (~4–6%). It further analyzes market dynamics—drivers like a surge in vaccine and biologic production, restraints including competition from polymers, opportunities tied to biologics and gene therapy growth, and challenges such as supply-chain bottlenecks and regulatory compliance. The report details competitive positioning, noting that the top 5 manufacturers supply approximately 50% of global demand, highlighting major players such as SCHOTT AG and Thermo Fisher Scientific. It also documents recent developments (e.g., 6 billion vial production milestone, rise of ready-to-fill systems, specialty glass vials, multi-dose trend, and new production capacities) and product innovations (amber vials, low-dead-volume, coated vials, recycled glass cullet usage). The Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Research Report and Market Forecast provide strategic insights for packaging suppliers, pharmaceutical companies, investors, and contract manufacturers planning capacity expansion, product investments, or supply-chain diversification in injectable drug packaging.

Glass Bottles and Vials for Vaccines & Pharmaceuticals Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 16183.12 Million in 2026
Market Size Value By	USD 25538.99 Million by 2035
Growth Rate	CAGR of 5.2% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Less than 30ml 30-80ml More than 80ml By Application : Vaccines General Medicine
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample